|
" A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer "
Minion, LE; Bai, J; Monk, BJ; Robin Keller, L; Ramez, EN; Forde, GK; Chan, JK; Tewari, KS
| Document Type
|
:
|
AL
|
| Record Number
|
:
|
913165
|
| Doc. No
|
:
|
LA7467f249
|
| Title & Author
|
:
|
A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer [Article]\ Minion, LE; Bai, J; Monk, BJ; Robin Keller, L; Ramez, EN; Forde, GK; Chan, JK; Tewari, KS
|
| Date
|
:
|
2015
|
| Title of Periodical
|
:
|
UC Irvine
|
| Abstract
|
:
|
© 2015 Elsevier Inc. All rights reserved. Objective To evaluate the cost-effectiveness of bevacizumab in recurrent/persistent and metastatic cervical cancer using recently reported updated survival and toxicology data. Methods A Markov decision tree based on the Gynecologic Oncology Group 240 randomized trial was created. The 2013 MediCare Services Drug Payment Table and Physician Fee Schedule provided costs. In the 5-year model subjects transitioned through the following states: response, progression, minor complications, severe complications, and death. Patients experiencing a health utility per month according to treatment effectiveness were calculated. Because cervical cancer survival is measured in months rather than years, results were reported in both quality adjusted cervical cancer life months and years (QALmonth, QALY), adjusted from a baseline of having advanced cervical cancer during a month. Results The estimated total cost of therapy with bevacizumab is approximately 13.2 times that for chemotherapy alone, adding
|
| |